FREELINE THERAPEUTICS HOLDIN (FRLN) Fundamental Analysis & Valuation

NASDAQ:FRLN • US35655L2060

6.48 USD
0 (0%)
At close: Feb 16, 2024
6.48 USD
0 (0%)
After Hours: 2/16/2024, 8:00:24 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This FRLN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

FRLN gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 519 industry peers in the Biotechnology industry. FRLN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. FRLN is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. FRLN Profitability Analysis

1.1 Basic Checks

  • In the past year FRLN has reported negative net income.
  • In the past year FRLN has reported a negative cash flow from operations.
FRLN Yearly Net Income VS EBIT VS OCF VS FCFFRLN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 -50M -100M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -101.44%, FRLN is doing worse than 79.22% of the companies in the same industry.
  • With a Return On Equity value of -166.21%, FRLN is not doing good in the industry: 70.44% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -101.44%
ROE -166.21%
ROIC N/A
ROA(3y)-79.36%
ROA(5y)-79.42%
ROE(3y)-108.32%
ROE(5y)-106.61%
ROIC(3y)N/A
ROIC(5y)N/A
FRLN Yearly ROA, ROE, ROICFRLN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 -50 -100 -150

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for FRLN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
FRLN Yearly Profit, Operating, Gross MarginsFRLN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. FRLN Health Analysis

2.1 Basic Checks

  • FRLN has more shares outstanding than it did 1 year ago.
  • FRLN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
FRLN Yearly Shares OutstandingFRLN Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 1M 2M 3M 4M
FRLN Yearly Total Debt VS Total AssetsFRLN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 50M 100M 150M 200M 250M

2.2 Solvency

  • Based on the Altman-Z score of -16.64, we must say that FRLN is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of -16.64, FRLN is not doing good in the industry: 88.34% of the companies in the same industry are doing better.
  • There is no outstanding debt for FRLN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -16.64
ROIC/WACCN/A
WACCN/A
FRLN Yearly LT Debt VS Equity VS FCFFRLN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 0 100M -100M 200M

2.3 Liquidity

  • A Current Ratio of 1.95 indicates that FRLN should not have too much problems paying its short term obligations.
  • Looking at the Current ratio, with a value of 1.95, FRLN is doing worse than 80.24% of the companies in the same industry.
  • FRLN has a Quick Ratio of 1.95. This is a normal value and indicates that FRLN is financially healthy and should not expect problems in meeting its short term obligations.
  • FRLN has a worse Quick ratio (1.95) than 78.72% of its industry peers.
Industry RankSector Rank
Current Ratio 1.95
Quick Ratio 1.95
FRLN Yearly Current Assets VS Current LiabilitesFRLN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. FRLN Growth Analysis

3.1 Past

  • The earnings per share for FRLN have decreased strongly by -49.48% in the last year.
EPS 1Y (TTM)-49.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%94.62%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 14.20% on average over the next years. This is quite good.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y97.48%
EPS Next 2Y29.2%
EPS Next 3Y28.42%
EPS Next 5Y14.2%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
FRLN Yearly Revenue VS EstimatesFRLN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2025 2026 2027 2028 2029 2030 100M 200M 300M
FRLN Yearly EPS VS EstimatesFRLN Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -10 -20 -30 -40 -50

More info and screens

Find the best growth stocksShow best growing peers

1

4. FRLN Valuation Analysis

4.1 Price/Earnings Ratio

  • FRLN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for FRLN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
FRLN Price Earnings VS Forward Price EarningsFRLN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FRLN Per share dataFRLN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20

4.3 Compensation for Growth

  • FRLN's earnings are expected to grow with 28.42% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.2%
EPS Next 3Y28.42%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. FRLN Dividend Analysis

5.1 Amount

  • FRLN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

FRLN Fundamentals: All Metrics, Ratios and Statistics

FREELINE THERAPEUTICS HOLDIN

NASDAQ:FRLN (2/16/2024, 8:00:24 PM)

After market: 6.48 0 (0%)

6.48

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13
Earnings (Next)02-29
Inst Owners1.99%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap28.24M
Revenue(TTM)625.00K
Net Income(TTM)-49.93M
Analysts80
Price Target8.41 (29.78%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-44.07%
EPS NQ rev (1m)0%
EPS NQ rev (3m)90.94%
EPS NY rev (1m)0%
EPS NY rev (3m)-8.47%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 45.18
P/FCF N/A
P/OCF N/A
P/B 0.94
P/tB 0.94
EV/EBITDA N/A
EPS(TTM)-25.95
EYN/A
EPS(NY)-8.58
Fwd EYN/A
FCF(TTM)-15.85
FCFYN/A
OCF(TTM)-14.81
OCFYN/A
SpS0.14
BVpS6.89
TBVpS6.89
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -101.44%
ROE -166.21%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-79.36%
ROA(5y)-79.42%
ROE(3y)-108.32%
ROE(5y)-106.61%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 313.6%
Cap/Sales 727.04%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.95
Quick Ratio 1.95
Altman-Z -16.64
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)237.65%
Cap/Depr(5y)259.13%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-49.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%94.62%
EPS Next Y97.48%
EPS Next 2Y29.2%
EPS Next 3Y28.42%
EPS Next 5Y14.2%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y39.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year18.96%
EBIT Next 3Y29.13%
EBIT Next 5Y17.65%
FCF growth 1Y23.52%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y27%
OCF growth 3YN/A
OCF growth 5YN/A

FREELINE THERAPEUTICS HOLDIN / FRLN FAQ

Can you provide the ChartMill fundamental rating for FREELINE THERAPEUTICS HOLDIN?

ChartMill assigns a fundamental rating of 2 / 10 to FRLN.


Can you provide the valuation status for FREELINE THERAPEUTICS HOLDIN?

ChartMill assigns a valuation rating of 1 / 10 to FREELINE THERAPEUTICS HOLDIN (FRLN). This can be considered as Overvalued.


Can you provide the profitability details for FREELINE THERAPEUTICS HOLDIN?

FREELINE THERAPEUTICS HOLDIN (FRLN) has a profitability rating of 0 / 10.


What is the financial health of FREELINE THERAPEUTICS HOLDIN (FRLN) stock?

The financial health rating of FREELINE THERAPEUTICS HOLDIN (FRLN) is 5 / 10.